Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
about
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesGenomic profiling in luminal breast cancerPrognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineHow reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and GynecopathologistsRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role.The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Multidisciplinary approach of early breast cancer: the biology applied to radiation oncology.Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Status of adjuvant endocrine therapy for breast cancer.Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerKi67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancerDifferential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.Absence of gamma-interferon-inducible lysosomal thiol reductase (GILT) is associated with poor disease-free survival in breast cancer patients.Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapyA simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.Prognostic and Predictive Markers for Treatment Decisions in Early Breast CancerPrediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Benefits and adverse effects of endocrine therapyWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyInterpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
P2860
Q24657145-36C3B1DE-D987-48C2-B0A8-DB361245D481Q26743510-B8FE78B8-1EFD-4FFA-A7AA-FF5B72910A15Q26862681-B2C0B7F5-5523-4C8A-84B2-61C9963E1D25Q27853207-3482DF83-CAA7-428F-9696-7AFBE43AFA0EQ28079118-BF689C6D-E02C-4F28-AC5B-EC27510DDDD0Q28729183-DFAB371C-A999-4A4D-9E33-BE393B33A1CEQ28730529-72E4ED1D-981A-4291-A610-AA22F5F30E30Q30318240-99C64FBC-59EA-4114-B13A-795DD29B5B0BQ30543788-E702B2D5-B8A6-45C0-9475-2105EF5CD0F9Q30652903-939736DF-C71E-4132-9B2C-8804D0E153A0Q33477635-33E2B1B0-B6BD-4E5A-8944-4C94FA140840Q33631047-17F64997-D213-4008-9C49-2C21668397FBQ33657595-C55B7559-DD6E-4146-9931-1E85DCF1238DQ33658276-2A1689D4-7A42-4B7D-8075-0C965A0AEACEQ33687123-9CC7BB13-3AA0-4282-8592-C859E65DBED0Q33692020-1340A2AC-9656-430D-9183-D56E34F01819Q33739138-A6CA15C0-9B30-4C07-AB03-5B5F6FBD43CBQ33843751-8D096552-30E6-4BA0-AE8D-03D3753F2251Q33944557-4EF77F1F-A34F-4AE1-80CC-D89FAA8EE49CQ33984087-F1FEDDCF-ACE8-48A8-A583-9644F1F3C52EQ34075697-977241B6-C311-402C-8B0A-A5AB9F26C60AQ34245787-07963CBF-A15F-492D-99B5-46DAF7BEB3DCQ34334262-5E8DE92A-52DC-420F-A3B8-3F1F09D65ACBQ34334964-AB4500BA-B57F-4792-8499-91AA20F7333CQ34379364-F1A92E64-AE0D-40E7-A09D-30AAC853A627Q34501788-919590C8-8604-4F3F-9E6D-E6C0D5403B02Q34577709-35EFB7A2-CDE0-46A4-971E-3D1A70C58C1EQ34633934-B1BCDC0B-B4A5-469C-8C4F-9F42EE35369AQ35051755-3B577C46-1BBF-4697-95F1-CABE50CC56EAQ35079079-A211E567-D233-4566-975D-1F901CD30EF6Q35095603-3E0BA807-AC21-4CBB-A2B6-F6259B762287Q35125648-BD08A061-BAC0-4326-8E22-621F370A6232Q35130819-4C5A0F37-BED8-4971-994C-F3C852C09994Q35135718-8D917635-8CE7-415C-AA6C-BF2B7770AE20Q35230273-D587CFEC-2E3A-419E-A77D-E9B277320D23Q35347732-A5A37F3B-A263-42C0-9825-8367E60C567BQ35440357-EE146DFB-0A68-4FCE-99A8-D0BB1D6C6DF2Q35462377-29E9BFB0-B2FE-4BAD-BD0E-5319C36DEDE7Q35557992-E48B067F-EF48-47DA-A979-A9134A06EEF9Q35566057-8EFA4513-966D-4480-8441-8B26E819ABCB
P2860
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@en
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@nl
type
label
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@en
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@nl
prefLabel
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@en
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@nl
P2093
P2860
P50
P356
P1476
Prognostic and predictive valu ...... vant tamoxifen with letrozole.
@en
P2093
Alan S Coates
Anita Giobbie-Hurder
Aron Goldhirsch
Barry A Gusterson
Beat Thürlimann
Breast International Group Trial 1-98
Christian Ohlschlegel
Fiona Knox
Gaëtan MacGrogan
Karen N Price
P2860
P304
P356
10.1200/JCO.2008.17.0829
P407
P577
2008-11-03T00:00:00Z